Sphingosine 1-phosphate signaling impacts lymphocyte migration, inflammation and infection

Pathogens and Disease

Volumn 74, Issue 6, 2016, Pages

  Tiper, Irina V ^a   East, James E ^a   Subrahmanyam, Priyanka B ^a   Webb, Tonya J ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

FTY720; Lymphocyte trafficking; S1P; Sphingosine

Indexed keywords

FINGOLIMOD; INTERLEUKIN 6; LYASE; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; CYTOKINE; IMMUNOSUPPRESSIVE AGENT; LYSOPHOSPHOLIPID; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE; TRANSCRIPTION FACTOR;

HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION; INFLAMMATION; LYMPHOCYTE MIGRATION; LYMPHOMA; MALIGNANT NEOPLASM; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; HEMATOLOGIC NEOPLASMS; HOST PATHOGEN INTERACTION; IMMUNE SYSTEM; IMMUNOLOGY; LYMPHOCYTE; METABOLISM; NEUTROPHIL CHEMOTAXIS;

ANIMALS; CHEMOTAXIS, LEUKOCYTE; CYTOKINES; DISEASE MODELS, ANIMAL; FINGOLIMOD HYDROCHLORIDE; HEMATOLOGIC NEOPLASMS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE AGENTS; INFECTION; INFLAMMATION; LYMPHOCYTES; LYSOPHOSPHOLIPIDS; SIGNAL TRANSDUCTION; SPHINGOSINE; TRANSCRIPTION FACTORS;

EID: 85011633527     PISSN: None     EISSN: 2049632X     Source Type: Journal    
DOI: 10.1093/femspd/ftw063     Document Type: Short Survey

References (85)

1. Anelli V, Gault CR, Cheng AB et al. Sphingosine kinase 1 is up-regulated during hypoxia in U87MG glioma cells. Role of hypoxia-inducible factors 1 and 2. J Biol Chem 2008;283: 3365-75
2. Antoon JW, White MD, Slaughter EM et al. Targeting NFkB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2. Cancer Biol Ther 2011;11:678-89
3. Arish M, Husein A, Kashif M et al. Sphingosine-1-phosphate signaling: unraveling its role as a drug target against infectious diseases. Drug Discov Today 2016;21:133-42
4. Baeyens A, Fang V, Chen C et al. Exit strategies: S1P signaling and t cell migration. Trends Immunol 2015;36:778-87
5. Bolli MH, Abele S, Birker M et al. Novel S1P(1) receptor agonists-part 3: from thiophenes to pyridines. J Med Chem 2014;57: 110-30
6. Brinkmann V, Billich A, Baumruker T et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 2010;9:883-97
7. Brinkmann V, Pinschewer DD, Feng L et al. FTY720: altered lymphocyte traffic results in allograft protection. Transplantation 2001;72:764-9
8. Budde K, Schmouder RL, Brunkhorst R et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol 2002;13:1073-83
9. Chiba K, Yanagawa Y, Masubuchi Y et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J Immunol 1998;160:5037-44
10. Chumanevich AA, Poudyal D, Cui X et al. Suppression of colitisdriven colon cancer in mice by a novel small molecule inhibitor of sphingosine kinase. Carcinogenesis 2010;31:1787-93
11. Cinamon G, Matloubian M, Lesneski MJ et al. Sphingosine 1-phosphate receptor 1 promotes B cell localization in the splenic marginal zone. Nat Immunol 2004;5:713-20
12. Daniel C, Sartory N, Zahn N et al. FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+CD25+ regulatory T cells. J Immunol 2007;178:2458-68
13. Dominguez MR, Ersching J, Lemos R et al. Re-circulation of lymphocytes mediated by sphingosine-1-phosphate receptor-1 contributes to resistance against experimental infection with the protozoan parasite Trypanosoma cruzi. Vaccine 2012;30:2882-91
14. Eigenbrod S, Derwand R, Jakl V et al. Sphingosine kinase and sphingosine-1-phosphate regulate migration, endocytosis and apoptosis of dendritic cells. Immunol Invest 2006;35: 149-65
15. Fitzpatrick LR, Green C, Maines LW et al. Experimental osteoarthritis in rats is attenuated by ABC294640, a selective inhibitor of sphingosine kinase-2. Pharmacology 2011;87: 135-43
16. French KJ, Zhuang Y, Maines LW et al. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J Pharmacol Exp Ther 2010;333:129-39
17. Gandhi AK, Kang J, Capone L et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Tar 2010;10:155-67
18. Garg SK, Santucci MB, Panitti M et al. Does sphingosine 1-phosphate play a protective role in the course of pulmonary tuberculosis? Clin Immunol 2006;121:260-4
19. Garg SK, Volpe E, Palmieri G et al. Sphingosine 1-phosphate induces antimicrobial activity both in vitro and in vivo. J Infect Dis 2004;189:2129-38
20. Gestaut MM, Antoon JW, Burow ME et al. Inhibition of sphingosine kinase-2 ablates androgen resistant prostate cancer proliferation and survival. Pharmacol Rep 2014;66:174-8
21. Goetzl EJ, Kong Y, Mei B. Lysophosphatidic acid and sphingosine 1-phosphate protection of T cells from apoptosis in association with suppression of Bax. J Immunol 1999;162:2049-56
22. Gohda M, Kunisawa J, Miura F et al. Sphingosine 1-phosphate regulates the egress of IgA plasmablasts from Peyer's patches for intestinal IgA responses. J Immunol 2008;180:5335-43
23. Graeler M, Goetzl EJ. Activation-regulated expression and chemotactic function of sphingosine 1-phosphate receptors in mouse splenic T cells. FASEB J 2002;16:1874-8
24. Green JA, Suzuki K, Cho B et al. The sphingosine 1-phosphate receptor S1P(2) maintains the homeostasis of germinal center B cells and promotes niche confinement. Nat Immunol 2011;12:672-80
25. Hait NC, Allegood J, Maceyka M et al. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science 2009;325:1254-7
26. Himmel HM, Meyer Zu Heringdorf D, Graf E et al. Evidence for Edg-3 receptor-mediated activation of I(K.ACh) by sphingosine-1-phosphate in human atrial cardiomyocytes. Mol Pharmacol 2000;58:449-54
27. Huang MC, Watson SR, Liao JJ et al. Th17 augmentation in OTII TCR plus T cell-selective type 1 sphingosine 1-phosphate receptor double transgenic mice. J Immunol 2007;178:6806-13
28. Hwang SJ, Kim JH, Kim HY et al. FTY720, a sphingosine 1-phosphate receptormodulator, inhibits CD1d-restricted NKT cells by suppressing cytokine production but not migration. Lab Invest 2010;90:9-19
29. Idzko M, Hammad H, van Nimwegen M et al. Local application of FTY720 to the lung abrogates experimental asthma by altering dendritic cell function. J Clin Invest 2006;116:2935-44
30. Idzko M, Panther E, Corinti S et al. Sphingosine 1-phosphate induces chemotaxis of immature and modulates cytokinerelease in mature human dendritic cells for emergence of Th2 immune responses. FASEB J 2002;16:625-7
31. Ito S, Iwaki S, Kondo R et al. TNF-alpha production in NKT cell hybridoma is regulated by sphingosine-1-phosphate: implications for inflammation in atherosclerosis. Coronary Artery Dis 2014;25:311-20
32. Jin Y, Knudsen E, Wang L et al. Sphingosine 1-phosphate is a novel inhibitor of T-cell proliferation. Blood 2003;101:4909-15
33. Johnson TA, Evans BL, Durafourt BA et al. Reduction of the peripheral blood CD56(bright) NK lymphocyte subset in FTY720-treated multiple sclerosis patients. J Immunol 2011;187:570-9
34. Jourdan M, Vos JD, Mechti N et al. Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1. Cell Death Differ 2000;7:1244-52
35. Kennedy AJ, Mathews TP, Kharel Y et al. Development of amidine-based sphingosine kinase 1 nanomolar inhibitors and reduction of sphingosine 1-phosphate in human leukemia cells. J Med Chem 2011;54:3524-48
36. Kunisawa J, Gohda M, Kurashima Y et al. Sphingosine 1-phosphate-dependent trafficking of peritoneal B cells requires functional NFkappaB-inducing kinase in stromal cells. Blood 2008;111:4646-52
37. Kunkel GT, Maceyka M, Milstien S et al. Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov 2013;12:688-702
38. Lam LT, Wright G, Davis RE et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-κB pathways in subtypes of diffuse large B-cell lymphoma. Blood 2007;111:3701-13
39. Li Q-F, Wu C-T, Duan H-F et al. Activation of sphingosine kinase mediates suppressive effect of interleukin-6 on humanmultiple myeloma cell apoptosis. Brit J Haematol 2007;138:632-9
40. Li Q-F, Wu C-T, Guo Q et al. Sphingosine 1-phosphate induces Mcl-1 upregulation and protects multiple myeloma cells against apoptosis. Biochem Bioph Res Co 2008;371:159-62
41. Liao JJ, Huang MC, Goetzl EJ. Cutting edge: alternative signaling of Th17 cell development by sphingosine 1-phosphate. J Immunol 2007;178:5425-8
42. Liu Q, Alinari L, Chen C-S et al. FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating cyclin D1 and phospho-Akt in mantle cell lymphoma. Clin Cancer Res 2010;16:3182-92
43. Liu Q, Zhao X, Frissora F et al. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood 2007;111:275-84
44. Liu Y, Deng J, Wang L et al. S1PR1 is an effective target to block STAT3 signaling in activated B cell-like diffuse large B-cell lymphoma. Blood 2012;120:1458-65
45. MaceykaM, Spiegel S. Sphingolipid metabolites in inflammatory disease. Nature 2014;510:58-67
46. Machesky NJ, Zhang G, Raghavan B et al. Human cytomegalovirus regulates bioactive sphingolipids. J Biol Chem 2008;283:26148-60
47. Mandala S, Hajdu R, Bergstrom J et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002;296:346-9
48. Martino A, Volpe E, Auricchio G et al. Sphingosine 1-phosphate interferes on the differentiation of human monocytes into competent dendritic cells. Scand J Immunol 2007;65:84-91
49. Matloubian M, Lo CG, Cinamon G et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004;427:355-60
50. MehlingM, Lindberg R, Raulf F et al. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology 2010;75:403-10
51. Mudd JC, Murphy P, Manion M et al. Impaired T-cell responses to sphingosine-1-phosphate in HIV-1 infected lymph nodes. Blood 2013;121:2914-22
52. Nagahashi M, Hait NC, Maceyka M et al. Sphingosine-1-phosphate in chronic intestinal inflammation and cancer. Adv Biol Regul 2014;54:112-20
53. Nam JH, Shin DH, Min JE et al. Ca2+ signaling induced by Sphingosine 1-phosphate and lysophosphatidic acid in mouse b cells. Mol Cells 2010;29:85-91
54. O'Brien N, Jones ST, Williams DG et al. Production and characterization of monoclonal anti-sphingosine-1-phosphate antibodies. J Lipid Res 2009;50:2245-57
55. Ogle ME, Sefcik LS, Awojoodu AO et al. Engineering in vivo gradients of sphingosine-1-phosphate receptor ligands for localized microvascular remodeling and inflammatory cell positioning. Acta Biomater 2014;10:4704-14
56. Paugh SW, Paugh BS, Rahmani M et al. A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia. Blood 2008;112:1382-91
57. Purschke WG, Hoehlig K, Buchner K et al. Identification and characterization of amirror-image oligonucleotide that binds and neutralizes Sphingosine-1-Phosphate, a central mediator of angiogenesis. Biochem J 2014, DOI: 10.1042/BJ20131422
58. Pyne NJ, Pyne S. Sphingosine 1-phosphate and cancer. Nat Rev Cancer 2010;10:489-503
59. Pyne S, Bittman R, Pyne NJ. Sphingosine kinase inhibitors and cancer: seeking the golden sword of Hercules. Cancer Res 2011;71:6576-82
60. Rolin J, Sand KL, Knudsen E et al. FTY720 and SEW2871 reverse the inhibitory effect of S1P on natural killer cell mediated lysis of K562 tumor cells and dendritic cells but not on cytokine release. Cancer Immunol Immun 2010;59:575-86
61. Rosen H, Sanna G, Alfonso C. Egress: a receptor-regulated step in lymphocyte trafficking. Immunol Rev 2003;195:160-77
62. Sanllehí P, Abad J-L, Casas J et al. Inhibitors of sphingosine-1-phosphate metabolism (sphingosine kinases and sphingosine-1-phosphate lyase). Chem Phys Lipids 2015, http://dx.doi.org/10.1016/j.chemphyslip.2015.07.007 (29 June 2016, date last accessed)
63. Sanna MG, Liao J, Jo E et al. Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem 2004;279: 13839-48
64. Schaper K, Kietzmann M, Baumer W. Sphingosine-1-phosphate differently regulates the cytokine production of IL-12, IL-23 and IL-27 in activatedmurine bone marrowderived dendritic cells. Mol Immunol 2014;59:10-8
65. Seo Y-J, Blake C, Alexander S et al. Sphingosine 1-phosphatemetabolizing enzymes control influenza virus propagation and viral cytopathogenicity. J Virol 2010;84:8124-31
66. Seo YJ, Pritzl CJ, Vijayan M et al. Sphingosine kinase 1 serves as a pro-viral factor by regulating viral RNA synthesis and nuclear export of viral ribonucleoprotein complex upon influenza virus infection. PLoS One 2013;8:e75005
67. Shimizu H, Takahashi M, Kaneko T et al. KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronic rejection in rat skin and heart allografts. Circulation 2005;111:222-9
68. Siveen KS, Sikka S, Surana R et al. Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors. BBA-Rev Cancer 2014;1845:136-54
69. Skerry C, Scanlon K, Rosen H et al. Sphingosine-1-phosphate receptor agonism reduces bordetella pertussis-mediated lung pathology. J Infect Dis 2015;211:1883-6
70. Snider AJ, Ruiz P, Obeid LM et al. Inhibition of sphingosine kinase-2 in a murine model of lupus nephritis. PLoS One 2013;8:e53521
71. St. John AL, Ang WXG, Huang M-N et al. S1P-dependent trafficking of intracellular Yersinia pestis through lymph nodes establishes buboes and systemic infection. Immunity 2014;41: 440-50
72. Suzuki S, Enosawa S, Kakefuda T et al. A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation. Transplantation 1996;61:200-5
73. Swaney JS, Moreno KM, Gentile AM et al. Sphingosine-1-phosphate (S1P) is a novel fibrotic mediator in the eye. Exp Eye Res 2008;87:367-75
74. Tong S, Tian J, Wang H et al. H9N2 avian influenza infection altered expression pattern of Sphiogosine-1-phosphate Receptor 1 in BALB/c mice. Virol J 2013;10:1-8
75. Vijayan M, Seo Y-J, Pritzl CJ et al. Sphingosine kinase 1 regulates measles virus replication. Virology 2014;450-451:55-63
76. Visentin B, Vekich JA, Sibbald BJ et al. Validation of an antisphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 2006;9:225-38
77. Voorhees P, Chen Q, Small GW et al. Targeted Inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death. Brit J Haematol 2009;145:481-90
78. Wallington-Beddoe CT, Hewson J, Bradstock KF et al. FTY720 produces caspase-independent cell death of acute lymphoblastic leukemia cells. Autophagy 2011;7:707-15
79. Walsh KB, Teijaro JR, Brock LG et al. Animal model of respiratory syncytial virus: cd8+ T cells cause a cytokine storm that is chemically tractable by sphingosine-1-phosphate 1 receptor agonist therapy. J Virol 2014;88:6281-93
80. Wuilleme-Toumi S, Robillard N, Gomez P et al. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia 2005;19:1248-52
81. Yagi H, Kamba R, Chiba K et al. Immunosuppressant FTY720 inhibits thymocyte emigration. Eur J Immunol 2000;30: 1435-44
82. Yanagawa Y, Sugahara K, Kataoka H et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivo. J Immunol 1998;160:5493-9
83. Yasui H, Hideshima T, Raje N et al. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. Cancer Res 2005;65:7478-84
84. Zhang Y, Wang Y, Wan Z et al. Sphingosine kinase 1 and cancer: a systematic review and meta-analysis. PLoS One 2014;9:e90362
85. Zheng Y, Kong Y, Goetzl EJ. Lysophosphatidic acid receptorselective effects on Jurkat T cell migration through a Matrigel model basement membrane. J Immunol 2001;166: 2317-22